CTI Life Sciences Fund Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 6
- Investments
- 36
- Portfolio
- 6
- Exits
- 19
CTI Life Sciences Fund General Information
Description
Founded in 2006 CTI Life Sciences Fund is a venture capital investment firm that is headquartered in Montreal, Canada. The firm prefers to invest in the life sciences and healthcare companies at the pre-clinical and clinical development stages located in the United States and Canada.
Contact Information
Website
www.ctisciences.com
Year Founded
2006
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Primary Office
- 1 Place Ville-Marie
- Bureau 1050
- Montreal, Quebec H3B 4S6
- Canada
+1 (514) 000-0000
CTI Life Sciences Fund Investments (36)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| VectivBio | 15-Oct-2020 | Later Stage VC | 00000 | Drug Discovery | Clinical Trials - Phase 3 | |
| 0000 000000000000 | 08-Jun-2020 | 00000 00000 | Drug Discovery | Generating Revenue | 00000000 0000000 00.0 | |
| 00000000 00 | 08-Jun-2020 | 0000 00000 | 000 | Discovery Tools (Healthcare) | Generating Revenue | 000000000 000000 00.0 |
| 0000000 | 26-Mar-2020 | 00000 00000 | 00000 | Drug Discovery | Startup | |
| 0000000 | 19-May-2018 | 00000 00000 | 0000 | Drug Discovery | Startup | |
| 00000000 | 05-Oct-2017 | 00000 00000 | 000.00 | Biotechnology | Generating Revenue | |
| 0000000000 | 27-Jul-2017 | 00000 00000 | 0000 | Biotechnology | Startup | 00000000 0000000 00.0 |
| 00000 0000000 | 27-Jun-2017 | 00000 00000 | 0000 | Network Management Software | Generating Revenue | 000000000 000000 00.0 |
| Vaxcyte | 21-Mar-2017 | Later Stage VC | 0000 | Drug Discovery | Startup | |
| CellAegis Devices | 10-Mar-2017 | Later Stage VC | 00.00 | Therapeutic Devices | Bankruptcy: Liquidation | 000000000 000000 00.0 |
CTI Life Sciences Fund Exits (19)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| VectivBio | 09-Apr-2021 | IPO | 00000 |
| 00000 00000000000 | 30-Dec-2020 | 000000000000000000 | |
| 00000000 0000000 | 21-Jul-2020 | 000000 0000000000 | 000.00 |
| 0000000 | 12-Jun-2020 | 000 | 00000 |
| 000000000 0000000 | 01-Jan-2020 | 0000000000: 000000 | |
| 000000000 | 09-Oct-2018 | 000000000000000000 | |
| 00000000 | 31-Aug-2018 | 000000000000000000 | 00000 |
| 00000 000000000000 | 01-Mar-2018 | 000 00 00000000 | |
| Xagenic | 25-Jan-2018 | Merger/Acquisition | |
| Xagenic | 28-Sep-2017 | Bankruptcy: Admin/Reorg |
CTI Life Sciences Fund Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialCTI Life Sciences Fund Team (9)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Mark Chadakhtzian | Chief Financial Officer & Chief Compliance Officer | Montreal, Canada | |||
| Jean-Francois Leprince | Managing Partner | 0 | 0 | 0 | Montreal, Canada |
| Shermaine Tilley Ph.D | Managing Partner | 00 | 0 | 0 | Montreal, Canada |
| Youssef Bennani Ph.D | Managing Partner | 0 | Montreal, Canada | ||
| Laurence Rulleau Ph.D | Managing Partner Fund II & III | 0 | 0 | 0 | Montreal, Canada |
CTI Life Sciences Fund Co-Investors (33)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Abingworth Management | 1 | 0 |
|
|
|
| Citadel (Hedge Fund) | 0 |
|
|
||
| Frazier Healthcare Partners | 0 | 0 |
|
|
|
| Novo Holdings | 0 | 0 |
|
|
|
| TPG | 0 |
|
|